NEW DELHI: The Drug Controller General of India has approved Sun Pharmaceutical Industries Ltd’s clinical trial with nafamostat mesilate in covid-19 patients.
Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of disseminated intravascular coagulation, a condition in which abnormal clumps of blood clots form inside blood vessels.
A group of scientists from the University of Tokyo in Japan and Leibniz Institute for Primate Research in Germany, however, have found that nafamostat, at very low concentrations, suppresses a protein that that the novel coronavirus uses to enter human lung cells, while another group from Institut Pasteur in South Korea found that the drug was able to inhibit virus